India, Nov. 11 -- With only a few days left for the FDA to deliver its verdict, Capricor Therapeutics Inc. (CAPR) faces a make-or-break moment. The regulatory decision could open the door to a new chapter for its investigational product or force the company to face a far more difficult road ahead.
Capricor's journey so far may be familiar to its longtime followers. For readers new to the story, however, it is worth turning back the pages to revisit the milestones that have shaped the company's path.
The Origins of Capricor
Founded in 2005, Capricor Inc. was a privately held biotechnology company established by Eduardo Marban, M.D., Ph.D., to develop therapeutic applications based on cardiosphere-derived cells (CDCs), a technology origina...